Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017

by Barry101 | Aug 15, 2017 | Press Release

The Company has Generated Revenues and Advanced in R&D for Intranasal Ampligen and in Immuno-OncologyConference Call Scheduled for Tuesday, August 15th at 1:00 PM EDTPHILADELPHIA, Aug. 15, 2017 — Hemispherx Biopharma (NYSE MKT:HEB): This quarter we see...

Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated

by Barry101 | Aug 14, 2017 | Press Release

PHILADELPHIA, Aug. 14, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist® known as AMP-600. The study was previously closed, but the initiation of...

Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017

by Barry101 | Aug 11, 2017 | Press Release

Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017PHILADELPHIA, Aug. 11, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its...

Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

by Barry101 | Aug 8, 2017 | Press Release

Advocacy Organization to Work with Health Canada with the Goal to Gain ApprovalPHILADELPHIA, Aug. 08, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian...

Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome

by Barry101 | Aug 4, 2017 | Press Release

Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue SyndromePHILADELPHIA, Aug. 04, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may...